Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study

BJU International
Claus G Roehrborn

Abstract

To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). In all, 1522 men at risk of having progression events from LUTS/BPH were randomized to receive alfuzosin 10 mg once daily (759) or placebo (763) for 2 years. Endpoints assessed were the occurrence of a first episode of acute urinary retention (AUR; primary) and the need for BPH-related surgery. Post hoc analyses included a deterioration in the International Prostate Symptom Score (IPSS) of > or = 4 points and overall clinical progression of BPH (occurrence of AUR and/or surgery and/or symptom deterioration). Over 2 years, symptom deterioration was the most common progression event (14.3%), followed by BPH-related surgery (5.8%) and AUR (2.0%). Alfuzosin did not reduce the risk of AUR (alfuzosin 2.1% vs placebo 1.8%, P = 0.82) but tended to reduce the risk of surgery (5.1% vs 6.5%, P = 0.18); the reduction in risk (RR) and 95% confidence interval with alfuzosin was 22 (-18 to 48)%; and significantly reduced the risk of symptom deterioration (11.7% vs 16.8%; P = 0.0013); the RR was 30 (10-46)%. The overall clinical progression of BPH was significantly...Continue Reading

Associated Clinical Trials

References

Feb 25, 2003·Urology·Mark EmbertonJ Curtis Nickel
Dec 19, 2003·The New England Journal of Medicine·John D McConnellUNKNOWN Medical Therapy of Prostatic Symptoms (MTOPS) Research Group
Feb 14, 2006·BJU International·Mostafa ElhilaliUNKNOWN ALF-ONE Study Group
Mar 2, 2006·BJU International·John M Fitzpatrick
Mar 2, 2006·BJU International·Claus G Roehrborn
Mar 2, 2006·BJU International·Mark Emberton

❮ Previous
Next ❯

Citations

Nov 13, 2008·International Journal of Impotence Research·C G Roehrborn
Sep 12, 2006·Nature Clinical Practice. Urology·Michael Marberger
Aug 4, 2007·Nature Clinical Practice. Urology·Jay KhastgirMark Speakman
Feb 16, 2012·Prostate Cancer and Prostatic Diseases·F Azzouni, J Mohler
Nov 18, 2006·International Journal of Clinical Practice·M J NaslundM M Miner
Jun 29, 2010·International Journal of Clinical Practice·M Emberton
Feb 20, 2007·Postgraduate Medical Journal·Stephen S Connolly, John M Fitzpatrick
Jan 30, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Frank P HurstKevin C Abbott
May 8, 2010·Expert Opinion on Emerging Drugs·Hashim Hashim, Paul Abrams
Jun 26, 2007·Current Medical Research and Opinion·Sebastiano SpataforaUNKNOWN AURO.it BPH Guidelines Committee
Sep 4, 2015·Annual Review of Medicine·Eric H KimGerald L Andriole
May 20, 2008·The Journal of Urology·Steven A KaplanWilliam D Steers
Mar 2, 2006·BJU International·John M Fitzpatrick
Mar 2, 2006·BJU International·Claus G Roehrborn
May 1, 2012·Lower Urinary Tract Symptoms·Jin Wook KimJeong Gu Lee
Jan 27, 2011·BJU International·Mark EmbertonJon Rees
Jun 11, 2009·International Journal of Andrology·B FibbiM Maggi
May 6, 2016·Nature Reviews. Disease Primers·Bilal ChughtaiSteven A Kaplan
Nov 8, 2012·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Luciana Ribeiro BahiaValter Javaroni
Aug 22, 2014·Current Opinion in Urology·Altaf Mangera, Christopher R Chapple
Mar 21, 2017·Urologia·Fabio ZattoniGiacomo Novara
Nov 28, 2018·The Cochrane Database of Systematic Reviews·Smita PattanaikArup K Mandal
Dec 6, 2008·Current Opinion in Urology·Jeremy Wiygul, Richard K Babayan
Jul 29, 2010·Korean journal of urology·Kyoung Pyo HongWoo Sik Chung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.